Global Locator
Genzyme Websites
Health Care Professionals
Company
Products
Research
Patients
Responsibility
Careers
News
About Genzyme
Company Leadership
Business Units
News
Press Contacts
Subscribe to News
Recognition and Awards
Working With Genzyme
Global Reach
Download Genzyme Materials
Today is April 27, 2024. All times in Eastern Daylight Time.
Relapsing Remitting MS Patients Who Received Lemtrada® (alemtuzumab) Reported Improvements in Treatment Satisfaction and Health-Related Quality of Life in Clinical Studies
05/06/2019 - 09:00 AM
Relapsing MS Patients Who Switched to Aubagio® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
04/23/2018 - 09:37 AM
Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada® (alemtuzumab) in Clinical Trials
04/23/2018 - 09:20 AM
More Than 25 Data Presentations from Sanofi Genzyme’s Multiple Sclerosis Franchise to Be Featured at AAN
04/19/2018 - 09:00 AM
Treatment Effects Maintained Over Five Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Extension Study After Switching from Interferon Beta-1a
10/27/2017 - 09:30 AM
New Data Suggest Slowing of Cortical Gray Matter Atrophy with Sanofi Genzyme’s Aubagio® (teriflunomide) is Associated with Delayed Conversion to Clinically Definite Multiple Sclerosis
10/26/2017 - 09:30 AM
Sanofi Genzyme Recognizes Ninth Annual World MS Day
05/31/2017 - 08:00 AM
New Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy
04/25/2017 - 08:30 AM
New Investigational Data on Six-Year Efficacy of Sanofi Genzyme’s Lemtrada® (alemtuzumab) in Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented at AAN
04/25/2017 - 08:00 AM
More than 30 Presentations of New Investigational Data from Sanofi Genzyme’s Multiple Sclerosis Franchise to be Featured at AAN
04/11/2017 - 09:00 AM
Sanofi Genzyme Recognizes Rare Disease Day 2017 with Programs of Events around the World
02/28/2017 - 07:45 AM
Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson’s Disease
02/14/2017 - 08:00 AM
Sanofi Genzyme Commitment to Patients with Rare Diseases Highlighted at WORLDSymposium 2017
02/09/2017 - 08:00 AM
Sanofi Genzyme Announces Recipients of 2016 Patient Advocacy Leadership (PAL) Awards
12/20/2016 - 09:45 AM
Sanofi Genzyme Announces Start of Phase III Study of Isatuximab for Relapsed and Refractory Multiple Myeloma
12/05/2016 - 12:50 PM
Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease
11/04/2016 - 08:00 AM
BARDA Awards $37.6 million Contract to Sanofi to Supply Leukine® (sargramostim) for Potential Public Health Emergency
10/06/2016 - 04:00 PM
Results from 1,000-Patient, Global Real-World Patient-Reported Outcomes Study of Sanofi Genzyme’s Aubagio® (teriflunomide) in Patients with Relapsing Multiple Sclerosis Demonstrate High Levels of Treatment Satisfaction
09/15/2016 - 10:45 AM
More than 35 Presentations of New Investigational Data from Sanofi Genzyme’s Multiple Sclerosis Franchise to be Featured at ECTRIMS
09/07/2016 - 08:00 AM
Sanofi Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency
07/06/2016 - 08:00 AM
Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis
05/25/2016 - 01:00 AM
Sanofi Genzyme Announces Multiple Sclerosis Research Collaboration with the Johns Hopkins School of Medicine
05/16/2016 - 09:00 AM
New Data Suggesting Positive Effects of Sanofi Genzyme’s Lemtrada® (alemtuzumab) on Brain Volume Loss and Retinal Nerve Fibers to be Presented at AAN
04/18/2016 - 09:00 AM
More than 35 Presentations of New Investigational Data from Sanofi Genzyme’s Multiple Sclerosis Franchise to be Featured at AAN
04/15/2016 - 10:00 AM
Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease
03/03/2016 - 05:00 PM
1
2
3
4
5
6
7
8
9
10
11
12
Next »
infoBox
LinkedIn
Yahoo! Buzz
Facebook
Twitter
Delicious
DIGG